

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Limited) Plot No. 23, Sector 22, Korangi Industrial Area, Karachi 74900, Pakistan

FORM-7

October 24, 2024

The General Manager

Pakistan Stock Exchange Limited Stock Exchange Building Stock Exchange Road Karachi -74000.

SUBJECT: FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024

Dear Sir

We are pleased to inform you that the Board of Directors of Hoechst Pakistan Limited (formerly Sanofi-Aventis Pakistan Limited) (the Company) in its meeting held on Wednesday, October 23, 2024 at 02:00 p.m. at Head Office of the Company and through video link arrangement has approved the condensed interim financial statements (un-audited) of the Company for the nine months ended September 30, 2024 and recommended the following:

(i) <u>CASH DIVIDEND</u>: Nil

(ii) <u>BONUS SHARES</u>: Nil

(iii) <u>RIGHT SHARES</u>: Nil

(iv) ANY OTHER ENTITLEMENT / CORPORATE ACTION: Nil

(v) ANY OTHER PRICE-SENSITIVE INFORMATION: Nil

The financial results of the Company for the nine months ended September 30, 2024 are enclosed as **Annexure** – \mathbf{A} to this letter.

The Quarterly Report of the Company for the nine months ended September 30, 2024 will be transmitted through PUCARS separately, within the specified time and shall also be made available on Company's website www.hoechst.com.pk.

Yours sincerely

Syed Muhammad Taha Naqvi

Company Secretary

Encl: As above.

Cc:

Director	Director	Director	Executive Director / HOD	
Company Law Division	Enforcement Department	Securities Market Division	Offsite-II Department	
Securities and Exchange	Securities and Exchange	Securities and Exchange	Supervision Division	
Commission of Pakistan	Commission of Pakistan	Commission of Pakistan	Securities and Exchange	
NIC Building, Jinnah	NIC Building, Jinnah	NIC Building, Jinnah	Commission of Pakistan	
Avenue Blue Area,	Avenue Blue Area,	Avenue Blue Area,	NIC Building, Jinnah	
Islamabad	Islamabad	Islamabad	Avenue Blue Area,	
			Islamabad	

Karachi 74900, Pakistan



Annexure A

Hoechst Pakistan Limited (formerly Sanofi-Aventis Pakistan Limited) Condensed Interim Statement of Profit or Loss

For the period ended September 30, 2024 (Un-audited)

	Nine Mon	Nine Months Ended		Quarter Ended	
	September 30, 2024	September 30, 2023 (Restated)	September 30, 2024	September 30, 2023 (Restated)	
		Rupees in '000			
REVENUE FROM CONTRACT WITH CUSTOMERS - NET	20,516,760	15,879,229	7,185,969	5,831,380	
Cost of sales	(14,224,194)	(11,547,720)	(4,678,174)	(4,046,218)	
GROSS PROFIT	6,292,566	4,331,509	2,507,795	1,785,162	
Distribution and marketing costs	(2,505,565)	(1,951,719)	(992,906)	(754,054)	
Administrative expenses	(788,359)	(686,168)	(264,137)	(263,685)	
Other expenses	(611,238)	(1,533,687)	(391,983)	(340,244)	
Other income	191,141	269,967	40,803	173,034	
	(3,714,021)	(3,901,607)	(1,608,223)	(1,184,949)	
OPERATING PROFIT	2,578,545	429,902	899,572	600,213	
Finance costs	(82,935)	(153,539)	(22,646)	(23,354)	
PROFIT BEFORE MINIMUM TAX DIFFERENTIAL,					
FINAL TAX AND INCOME TAX	2,495,610	276,363	876,926	576,859	
Minimum tax differential	(310,997)	(212,924)	(133,921)	(143)	
Final tax	(35,019)	(6,992)	(4,080)	(4,088)	
PROFIT BEFORE INCOME TAX	2,149,594	56,447	738,925	572,628	
Taxation - Current	(957,581)	(188,668)	(392,118)	(181,752)	
- Deferred	12,896	79,389	32,099	78,622	
	(944,685)	(109,279)	(360,019)	(103,130)	
PROFIT / (LOSS) FOR THE PERIOD	1,204,909	(52,832)	378,906	469,498	
EARNINGS / (LOSS) PER SHARE - basic and diluted (Rupees)	124.93	(5.48)	39.29	48.68	



